Importance:
With improved survival, heart failure (HF) has become a major complication for individuals with human immunodeficiency virus (HIV) infection. It is unclear if this risk extends to different types of HF in the antiretroviral therapy (ART) era. Determining whether HIV infection is associated with HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), or both is critical because HF types differ with respect to underlying mechanism, treatment, and prognosis.
Objectives:
To investigate whether HIV infection increases the risk of future HFrEF and HFpEF and to assess if this risk varies by sociodemographic and HIV-specific factors.
Design, Setting, And Participants:
This study evaluated 98 015 participants without baseline cardiovascular disease from the Veterans Aging Cohort Study, an observational cohort of HIV-infected veterans and uninfected veterans matched by age, sex, race/ethnicity, and clinical site, enrolled on or after April 1, 2003, and followed up through September 30, 2012. The dates of the analysis were October 2015 to November 2016.
Exposure:
Human immunodeficiency virus infection.
Main Outcomes And Measures:
Outcomes included HFpEF (EF≥50%), borderline HFpEF (EF 40%-49%), HFrEF (EF<40%), and HF of unknown type (EF missing).
Results:
Among 98 015 participants, the mean (SD) age at enrollment in the study was 48.3 (9.8) years, 97.0% were male, and 32.2% had HIV infection. During a median follow-up of 7.1 years, there were 2636 total HF events (34.6% were HFpEF, 15.5% were borderline HFpEF, 37.1% were HFrEF, and 12.8% were HF of unknown type). Compared with uninfected veterans, HIV-infected veterans had an increased risk of HFpEF (hazard ratio [HR], 1.21; 95% CI, 1.03-1.41), borderline HFpEF (HR, 1.37; 95% CI, 1.09-1.72), and HFrEF (HR, 1.61; 95% CI, 1.40-1.86). The risk of HFrEF was pronounced in veterans younger than 40 years at baseline (HR, 3.59; 95% CI, 1.95-6.58). Among HIV-infected veterans, time-updated HIV-1 RNA viral load of at least 500 copies/mL compared with less than 500 copies/mL was associated with an increased risk of HFrEF, and time-updated CD4 cell count less than 200 cells/mm3 compared with at least 500 cells/mm3 was associated with an increased risk of HFrEF and HFpEF.
Conclusions And Relevance:
Individuals who are infected with HIV have an increased risk of HFpEF, borderline HFpEF, and HFrEF compared with uninfected individuals. The increased risk of HFrEF can manifest decades earlier than would be expected in a typical uninfected population. Future research should focus on prevention, risk stratification, and identification of the mechanisms for HFrEF and HFpEF in the HIV-infected population.
Citing Articles
Proinflammatory Biomarkers and Clinical Factors Associated with Long-Term Mortality in People with HIV.
Lembas A, Zaleski A, Mikula T, Kozlowska J, Wiercinska-Drapalo A
Viruses. 2025; 17(2).
PMID: 40006998
PMC: 11860511.
DOI: 10.3390/v17020243.
Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.
Biscetti F, Polito G, Rando M, Nicolazzi M, Eraso L, DiMuzio P
Int J Mol Sci. 2025; 26(2).
PMID: 39859250
PMC: 11765428.
DOI: 10.3390/ijms26020535.
Proteomic signature of HIV-associated subclinical left atrial remodeling and incident heart failure.
Peterson T, Hahn V, Moaddel R, Zhu M, Haberlen S, Palella F
Nat Commun. 2025; 16(1):610.
PMID: 39800750
PMC: 11725572.
DOI: 10.1038/s41467-025-55911-0.
Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status.
Lo Re 3rd V, Newcomb C, Carbonari D, Mezochow A, Hennessy S, Rentsch C
Pharmacoepidemiol Drug Saf. 2024; 33(12):e70069.
PMID: 39662972
PMC: 11634562.
DOI: 10.1002/pds.70069.
HIV-Associated Heart Failure: Phenotypes and Clinical Outcomes in a Safety-Net Setting.
Durstenfeld M, Thakkar A, Jeon D, Short R, Ma Y, Tseng Z
J Am Heart Assoc. 2024; 13(23):e036467.
PMID: 39575755
PMC: 11681565.
DOI: 10.1161/JAHA.124.036467.
Optimizing cardiometabolic risk in people living with human immunodeficiency virus: A deep dive into an important risk enhancer.
Kobe E, Thakkar A, Matai S, Akkaya E, Pagidipati N, McGarrah R
Am J Prev Cardiol. 2024; 20:100888.
PMID: 39552706
PMC: 11566711.
DOI: 10.1016/j.ajpc.2024.100888.
Associations of HIV and prevalent type 2 diabetes mellitus in the context of obesity in South Africa.
Magodoro I, Castle A, Tshuma N, Goedecke J, Sewpaul R, Manasa J
J Multimorb Comorb. 2024; 14:26335565241293691.
PMID: 39492946
PMC: 11528680.
DOI: 10.1177/26335565241293691.
Demographic and clinical characteristics of New York City Health + Hospitals HIV Heart Failure (NYC4H cohort): cohort profile.
Chen Y, Borkowski P, Nazarenko N, Biavati L, Parker M, Chowdhury I
BMJ Open. 2024; 14(10):e085081.
PMID: 39477254
PMC: 11529568.
DOI: 10.1136/bmjopen-2024-085081.
Evolution of heart transplant donor characteristics in the 21 century: A United States single center's experience.
Spring A, Gjelaj C, Madan S, Patel S, Saeed O, Murthy S
World J Transplant. 2024; 14(3):92721.
PMID: 39295977
PMC: 11317857.
DOI: 10.5500/wjt.v14.i3.92721.
Cardiovascular disease risk in people of African ancestry with HIV in the United Kingdom.
Ko S, Dominguez-Dominguez L, Ottaway Z, Campbell L, Fox J, Burns F
HIV Med. 2024; 25(12):1289-1297.
PMID: 39209512
PMC: 11608579.
DOI: 10.1111/hiv.13706.
Evaluating the Efficacy of Psycho-Behavioral Interventions for Cardiovascular Risk among People Living with HIV: A Systematic Review and Meta-Synthesis of Randomized Controlled Trials.
Foley J, Bernier L, Ngo L, Batchelder A, OCleirigh C, Lydston M
J Acquir Immune Defic Syndr. 2024; 96(4):399-409.
PMID: 39175844
PMC: 11338626.
DOI: 10.1097/qai.0000000000003441.
Beyond HIV Shame: Effects of Self-Forgiveness in Improving Mental Health in HIV-Positive Individuals in Poland.
Skalski-Bednarz S, Toussaint L, Surzykiewicz J
J Relig Health. 2024; 63(6):4232-4254.
PMID: 39096441
PMC: 11576819.
DOI: 10.1007/s10943-024-02084-7.
Heart Failure With Preserved Ejection Fraction and Frailty: From Young to Superaged Coexisting HFpEF and Frailty.
Rakisheva A, Soloveva A, Shchendrygina A, Giverts I
Int J Heart Fail. 2024; 6(3):93-106.
PMID: 39081641
PMC: 11284337.
DOI: 10.36628/ijhf.2023.0064.
Microvascular Changes during Viral Infections: A Systematic Review of Studies Using Retinal Vessel Diameter Assessments.
Salon A, De Boever P, Goswami N
Biomedicines. 2024; 12(7).
PMID: 39062061
PMC: 11274461.
DOI: 10.3390/biomedicines12071488.
Signals From Inflamed Perivascular Adipose Tissue Contribute to Small-Vessel Dysfunction in Women With Human Immunodeficiency Virus.
Wilcox C, Herbert C, Wang C, Ma Y, Sun P, Li T
J Infect Dis. 2024; 230(1):67-77.
PMID: 39052698
PMC: 11272057.
DOI: 10.1093/infdis/jiae094.
Viral cardiovascular surgical diseases: global burdens, challenges and opportunities.
Gomes Z, Lee G, Mesfin S, Rocha R, Vervoort D
Future Cardiol. 2024; 20(4):229-239.
PMID: 39049768
PMC: 11285285.
DOI: 10.1080/14796678.2024.2348382.
Outcomes of Patients Living with HIV Hospitalized due to COVID-19: A 3-Year Nationwide Study (2020-2022).
Garcia-Carretero R, Vazquez-Gomez O, Rodriguez-Maya B, Gil-Prieto R, Gil-de-Miguel A
AIDS Behav. 2024; 28(9):3093-3102.
PMID: 38963568
PMC: 11390775.
DOI: 10.1007/s10461-024-04394-z.
Precision Phenotyping of Heart Failure in People with HIV: Early Insights and Challenges.
Grunblatt E, Feinstein M
Curr Heart Fail Rep. 2024; 21(4):417-427.
PMID: 38940893
DOI: 10.1007/s11897-024-00674-w.
Lack of Association of Vascular Risk Factors with HIV-Associated Neurocognitive Disorders in cART-Treated Adults Aged ≥ 50 Years in Tanzania.
Flack K, Rainey E, Urasa S, Koipapi S, Kalaria R, Howlett W
Viruses. 2024; 16(6).
PMID: 38932112
PMC: 11209468.
DOI: 10.3390/v16060819.
Gut microbiome and cardiometabolic comorbidities in people living with HIV.
Troseid M, Nielsen S, Vujkovic-Cvijin I
Microbiome. 2024; 12(1):106.
PMID: 38877521
PMC: 11177534.
DOI: 10.1186/s40168-024-01815-y.